Novartis Pharma AG (NVS) Obtains Rights From Otsuka Pharmaceutical Co., Ltd. To Develop New Treatment For Dry Eye
10/19/2005 5:12:38 PM
BASEL, Switzerland, Feb. 7, 2005 (PRIMEZONE) -- Novartis announced today that it has in-licensed rebamipide, an investigational treatment for dry eye, from Otsuka Pharmaceutical Company, Ltd. Currently being tested in two Phase III studies in the U.S., rebamipide is expected to demonstrate a novel mechanism of action to enhance tear secretion and increase the levels of mucin covering the conjunctiva and cornea of the eye.
comments powered by